Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Preferred Stock Liabilities (2019 - 2020)

Pliant Therapeutics has reported Preferred Stock Liabilities over the past 2 years, most recently at $62.5 million for Q1 2020.

  • Quarterly Preferred Stock Liabilities changed N/A to $62.5 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $62.5 million through Mar 2020, changed N/A year-over-year, with the annual reading at $47.9 million for FY2019, N/A changed from the prior year.
  • Preferred Stock Liabilities was $62.5 million for Q1 2020 at Pliant Therapeutics, up from $47.9 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $74.7 million in Q3 2019 and troughed at $47.9 million in Q4 2019.